Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Metastatic Colorectal Cancer Patients
Status:
Completed
Trial end date:
2020-10-05
Target enrollment:
Participant gender:
Summary
Single arm Phase I/II multicentric open labeled, with translational sub-study, of avelumab
plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS)
metastatic colorectal cancer patients..
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Grupo Espanol Multidisciplinario del Cancer Digestivo